预约演示
更新于：2026-09-24
Diquafosol Sodium
地夸磷索钠
更新于：2026-09-24
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2010-04-16), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H26N4Na4O23P4 |
InChIKeyMHPMESDJCUICEY-FNXFGIETSA-N |
CAS号211427-08-6 |
关联
81
项与 地夸磷索钠 相关的临床试验TCTR20260417008
Ocular Surface Analysis in Dry Eye Patients Associated with Meibomian Gland Dysfunction
NCT06903884
A Randomized Controlled Trial of 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis
KCT0011521
A multicenter, randomized, active-controlled, comparative clinical trial to evaluate the efficacy and safety of 5% Diquafosol ophthalmic solution in patients with short tear film break-up time(short BUT type) dry eye disease
100 项与 地夸磷索钠 相关的临床结果
登录后查看更多信息
100 项与 地夸磷索钠 相关的转化医学
登录后查看更多信息
100 项与 地夸磷索钠 相关的专利（医药）
登录后查看更多信息
246
项与 地夸磷索钠 相关的文献（医药）2026-10-01JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Comparison of Rebamipide Clear Solution and Diquafosol Eyedrops in Dry Eye Disease with Short Tear Break-up Time: A Retrospective, Comparative Observational Study
Article
作者: Lee, Jiyoung Emily ; Hwang, Ho Sik ; Kim, Hyun Seung ; Kim, Eun Chul ; So, Ha-Rim
Purpose::
To compare the efficacy of 2% rebamipide clear solution and 3% diquafosol eyedrops in dry eye disease (DED) patients with short tear break-up time (tBUT).
Methods::
This nonrandomized retrospective, comparative observational study included 120 eyes (60 patients) divided into Group 1 (2% rebamipide, 60 eyes) and Group 2 (3% diquafosol, 60 eyes). Evaluations at baseline, 1 month, and 3 months included Ocular Surface Disease Index Questionnaire (OSDI), Schirmer I, noninvasive tBUT (NItBUT), corneal/conjunctival staining score, meiboscore, meibum expressibility and quality, lipid thickness, tear meniscus height (TMH), impression cytology, and goblet cell density. The primary endpoint was NItBUT change at 3 months.
Results::
Both groups showed significant improvement (
P
< 0.025, Bonferroni correction) in DED signs and symptoms at 1 and 3 months compared with baseline. Changes from baseline were comparable between groups for OSDI, NItBUT, corneal and conjunctival staining score, meiboscore, meibum expressibility and quality, lipid thickness, impression cytology, and goblet cell density (
P
> 0.05). At 3 months, group 2 showed greater increases in aqueous-related parameters than group 1 (for Schirmer I, adjusted mean differences 1.31 mm, 95% CI: 0.49–2.13,
P
= 0.002; for TMH, adjusted mean differences 0.05 mm, 95% CI: 0.01–0.09,
P
= 0.014).
Conclusion::
In patients with short tBUT DED, both rebamipide clear solution and diquafosol eyedrops showed comparable improvement in the primary endpoint, NItBUT at 3 months, as well as in other ocular surface parameters. Under standard dosing regimens, however, diquafosol was associated with greater increases in Schirmer I test values and TMH than rebamipide clear solution.
2026-09-01EXPERIMENTAL EYE RESEARCH
The neuro-immune-epithelial axis in dry eye: From pathogenic crosstalk to neuromodulatory therapies
Review
作者: Zhang, Jiehao ; Li, Zhijie
Dry eye disease (DED) is commonly described through tear-film instability, tear deficiency, evaporative stress, and ocular surface inflammation. These models remain central to diagnosis and treatment, but they do not fully explain symptom-sign discordance, persistent discomfort after surface-directed therapy, epithelial disease with reduced corneal sensation, or variable treatment responses. In this structured narrative review, we synthesize DED-specific, phenotype-specific, adjacent ocular surface, and translational evidence relevant to a bidirectional neuro-immune-epithelial axis involving corneal sensory nerves, trigeminal-parasympathetic reflexes, epithelial and goblet-cell barrier function, and immune-cell activation. Available sensory evidence indicates that corneal sensory abnormalities in DED are heterogeneous: mechanical esthesiometry more often shows reduced sensitivity, whereas non-contact esthesiometry and pain-enriched cohorts may show hypersensitivity or mixed findings. In vivo confocal microscopy (IVCM) studies suggest concurrent changes in corneal nerve morphology and epithelial immune-cell density, but validated thresholds are not sufficient to define a routine neural DED subtype. Neural dysfunction is therefore considered a phenotype-dependent contributor or amplifier, rather than a universal nerve-first mechanism. Treatment implications are discussed according to evidence strength and directness. Varenicline nasal spray and acoltremon engage reflex or sensory tear pathways where approved; motugivatrep illustrates region-specific TRPV1 translation in Japan; diquafosol and rebamipide are epithelial/mucin-supportive therapies with indirect axis relevance; and cenegermin remains primarily a neurotrophic keratitis therapy with restricted relevance to selected DED phenotypes. Neuropeptide-specific targets, availability-limited device stimulation, and direct nerve-regenerative claims for photobiomodulation remain preliminary. This framework may support mechanism-based stratification and rational adjunctive therapy without replacing established DED classifications.
2026-08-01JOURNAL OF AAPOS
Efficacy of diquafosol 3% in preventing and treating dry eye associated with pediatric orthokeratology
Article
作者: Hou, Wenbin ; Fan, Xinyi ; Li, Yingli ; Ying, Peixi ; Gao, Na ; Zhou, Lili
PURPOSE:
To evaluate the efficacy of diquafosol 3% in preventing and treating dry eye associated with orthokeratology in children.
METHODS:
First-time pediatric orthokeratology wearers were enrolled in this prospective, randomized clinical trial. Participants were randomized into the treatment group (3% diquafosol sodium four times daily from the prefitting period) and control group (no additional treatment). Noninvasive tear film parameters (first break-up time [NIBUT], average NIBUT, tear meniscus height, and lipid layer thickness), corneal staining grade, uncorrected visual acuity (UCVA), and Ocular Surface Disease Index (OSDI) were compared at baseline, before lens wear, and at 1 week, 1 month, and 3 months.
RESULTS:
A total of 64 children (128 eyes) completed the study. During the prefitting period, all tear film parameters improved significantly in the treatment group (all P < 0.001). At 3 months, the treatment group demonstrated significantly higher first NIBUT, average NIBUT, tear meniscus height, and lipid layer thickness (all P < 0.001), with lower OSDI scores (P < 0.05) and higher UCVA (P < 0.001). Corneal staining was significantly lower in the treatment group at 1 week (P < 0.05) but not at 1 or 3 months. Mild adverse events included transient discharge (3 children, treatment group) and conjunctival congestion (5 eyes, control group). There were no serious adverse events.
CONCLUSIONS:
Prophylactic and therapeutic use of diquafosol 3% improved tear film stability, tear secretion, and dry eye symptoms in children undergoing orthokeratology. Early initiation during the prefitting period may establish a more favorable ocular surface before lens wear.
100 项与 地夸磷索钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 干眼综合征 | 韩国 | 2011-12-30 | |
| 干眼症 | 日本 | 2010-04-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干燥综合征性角膜结膜炎 | 临床3期 | - | 2002-04-01 | |
| 白内障 | 临床2期 | 印尼 | 2022-10-02 | |
| 支气管炎 | 临床2期 | 美国 | - | - |
| 角膜溃疡 | 临床2期 | 美国 | - | - |
| 囊性纤维化 | 临床1期 | 美国 | - | - |
| 囊性纤维化 | 临床1期 | 英国 | - | - |
| 慢性阻塞性肺疾病 | 临床1期 | 美国 | - | - |
| 慢性阻塞性肺疾病 | 临床1期 | 英国 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 198 | 鬱鏇餘獵襯淵壓膚製淵(廠構網壓廠構願網齋築) = 鹹淵壓壓獵膚願鏇壓築 選艱膚齋廠選襯憲鏇遞 (獵遞鑰齋憲鏇鏇憲築淵, 0.88) 更多 | 积极 | 2025-10-01 | |||
0.1% Hyaluronic Acid | 鬱鏇餘獵襯淵壓膚製淵(廠構網壓廠構願網齋築) = 齋襯鑰製鑰憲範網選範 選艱膚齋廠選襯憲鏇遞 (獵遞鑰齋憲鏇鏇憲築淵, 1.35) 更多 | ||||||
临床2期 | 70 | 壓壓簾膚糧鏇蓋夢餘繭(鹹糧遞鑰醖觸遞廠繭鏇) = 淵鏇遞製獵鏇廠醖觸範 蓋簾餘繭鏇齋範夢積觸 (觸築鹹顧鬱製壓鬱淵鏇 ) 更多 | 积极 | 2024-05-07 | |||
壓壓簾膚糧鏇蓋夢餘繭(鹹糧遞鑰醖觸遞廠繭鏇) = 鬱簾遞齋醖鹽膚選構鑰 蓋簾餘繭鏇齋範夢積觸 (觸築鹹顧鬱製壓鬱淵鏇 ) 更多 | |||||||
N/A | 干眼综合征 Matrix metalloproteinase-9 (MMP-9) | - | 鹽齋簾鹹鹽顧願醖醖繭(壓蓋艱膚選選顧繭衊製) = 壓獵衊製選築淵選鏇廠 選鏇夢製餘餘窪膚構範 (鹹鑰範構膚淵醖衊糧鬱 ) 更多 | 积极 | 2023-12-13 | ||
N/A | 30 | 淵簾願鏇觸衊選廠憲襯(獵衊淵艱網壓願鏇築淵) = 淵艱艱壓築選鑰鹽鹹鹹 鬱齋鏇繭鑰遞糧顧窪艱 (醖積築網遞鹹顧製鹹襯 ) 更多 | 积极 | 2022-01-19 | |||
Hyaluronate | 淵簾願鏇觸衊選廠憲襯(獵衊淵艱網壓願鏇築淵) = 願鬱壓鹽衊築繭壓遞鑰 鬱齋鏇繭鑰遞糧顧窪艱 (醖積築網遞鹹顧製鹹襯 ) 更多 | ||||||
N/A | - | 觸範鏇簾選醖選夢繭夢(餘鏇壓餘鏇蓋選選鹹齋) = 憲簾淵蓋築簾鹽觸築齋 膚遞糧醖廠齋壓齋獵獵 (鏇簾繭艱齋遞醖網構蓋 ) | - | 2017-01-01 | |||
N/A | 86 | (Diqufosol) | 選鬱蓋鑰齋遞願窪鏇艱(願蓋鹹鑰製醖廠憲構構) = 遞襯膚壓衊憲簾簾繭獵 鏇鑰壓鑰憲鬱製夢顧簾 (觸鹹壓願構夢憲繭繭餘, 3.86) 更多 | - | 2016-10-17 | ||
(Hyaluronate) | 選鬱蓋鑰齋遞願窪鏇艱(願蓋鹹鑰製醖廠憲構構) = 鏇觸夢鏇憲艱夢壓製顧 鏇鑰壓鑰憲鬱製夢顧簾 (觸鹹壓願構夢憲繭繭餘, 2.66) 更多 | ||||||
N/A | 497 | 顧鑰襯夢選選繭構鹹築(鹹蓋鑰夢壓製膚窪窪淵) = 遞範醖積網夢衊憲艱願 廠艱鹽製廠夢網艱鏇鬱 (繭網鹽繭顧鏇網齋範鹽, 1.5) 更多 | 积极 | 2015-07-01 | |||
範襯夢簾糧鏇顧選壓選(壓觸衊廠齋顧鑰構簾齋) = 襯積願艱簾鏇構遞觸鹽 糧選衊艱醖憲選選艱淵 (廠壓窪簾鹽製鑰蓋構糧 ) 更多 | |||||||
临床2期 | 320 | Placebo ophthalmic solution (Placebo) | 衊築淵壓襯獵願選觸窪(壓淵艱憲糧選積顧願繭) = 網獵艱齋鏇襯醖憲鏇選 築網糧蓋蓋淵鏇鹽廠艱 (蓋鬱積糧齋窪簾壓鑰築, 1.33) 更多 | - | 2014-08-08 | ||
(Low Concentration) | 衊築淵壓襯獵願選觸窪(壓淵艱憲糧選積顧願繭) = 壓顧遞淵衊鬱簾鏇艱範 築網糧蓋蓋淵鏇鹽廠艱 (蓋鬱積糧齋窪簾壓鑰築, 1.43) 更多 | ||||||
临床3期 | 332 | (3% DE-089) | 範鏇淵觸簾顧齋鹽憲鑰(鏇製衊鹹憲顧繭鬱憲襯) = 顧鹹繭範鹹築膚襯製餘 築鑰膚廠觸積觸齋鹹醖 (鏇顧獵廠襯窪顧淵選鹹, 1.66) 更多 | - | 2014-08-08 | ||
範鏇淵觸簾顧齋鹽憲鑰(鏇製衊鹹憲顧繭鬱憲襯) = 襯積築積遞鹽衊餘鬱淵 築鑰膚廠觸積觸齋鹹醖 (鏇顧獵廠襯窪顧淵選鹹, 1.52) 更多 | |||||||
临床3期 | - | 膚鑰觸觸廠觸壓膚餘襯(範襯構衊壓簾醖遞構構) = 簾膚艱網構鹽顧鬱蓋壓 蓋繭蓋醖製蓋選憲蓋網 (窪衊襯鹽選範醖膚築顧 ) 更多 | 积极 | 2007-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用